Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 BCR-ABL
- Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/261
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Dasatinib,Nilotinib
- Evidence Level
- A
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 20537386